临床试验与长期观察队列中系统性硬化症相关间质性肺病的预后与预测标志物
在 focuSSced 3 期试验的 68 例安慰剂组和 68 例托珠单抗组 SSc-ILD 患者及 SMART 真实世界队列 505 例 SSc-ILD 患者中,男性性别和炎症标志物与更低的 FVC 相关,两个队列的预后标志物相似,IL-6≥10 pg/ml 不能预测托珠单抗应答。
要点
- 安慰剂组中男性较女性 FVC 周下降快 0.22%(P=0.0001),CRP>6 mg/ml 者 FVC 较 CRP≤6 mg/ml 者低 9.8%(P=0.0059)。
- 托珠单抗降低男性、病程<2 年、IL-6<10 pg/ml 或抗拓扑异构酶抗体阳性患者 ppFVC 下降≥10% 的风险。
- SMART 队列中男性较女性发病 1 年后 FVC 低 3.3%(P<0.001),年下降快 0.6%(P=0.03)。
核心结论
- focuSSced 与 SMART 中 SSc-ILD 的预后标志物相似;男性性别和炎症标志物与更低 FVC 相关,但 IL-6≥10 pg/ml 不能预测托珠单抗应答。
研究设计与样本
- focuSSced 3 期试验 SSc-ILD 亚组纳入 106 例安慰剂组中的 68 例和 104 例托珠单抗组中的 68 例。
- SMART 真实世界队列纳入 505 例 SSc-ILD 患者。
- 采用线性混合效应模型分析 FVC 变化相关因素,Kaplan-Meier 估计和 Cox 回归用于时间-事件分析。
主要发现
- 安慰剂组中男性较女性 ppFVC 绝对下降≥10% 的风险增加,FVC 周下降快 0.22%(P=0.0001)。
- 安慰剂组中 CRP>6 mg/ml 者 FVC 较 CRP≤6 mg/ml 者低 9.8%(P=0.0059)。
- 托珠单抗降低男性、病程<2 年、IL-6<10 pg/ml 或 ATA 阳性患者 ppFVC 下降≥10% 的风险。
- SMART 队列中 ppFVC<70% 的预后因素为男性、ATA 和基线低 FVC。
- SMART 队列中男性较女性发病 1 年后 FVC 低 3.3%(P<0.001),年下降快 0.6%(P=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore prognostic and predictive markers of SSc-associated interstitial lung disease (SSc-ILD) outcomes in a phase 3 trial (focuSSced) and prognostic markers in a real-world cohort (SMART). METHODS: The focuSSced SSc-ILD subgroup included 68 of 106 placebo-treated and 68 of 104 tocilizumab-treated patients. The SMART cohort included 505 patients with SSc-ILD. Linear mixed-effect models were used to identify factors associated with change in forced vital capacity (FVC). Kaplan-Meier estimation and Cox regression were used for time-to-event analyses. RESULTS: In placebo-treated focuSSced patients, sex was a significant prognostic factor for FVC decline; males had increased risk for absolute decline ≥10% in percent-predicted FVC (ppFVC) and 0.22% faster weekly FVC decline than females (P = 0.0001). FVC was 9.8% lower in patients with CRP >6 mg/ml vs those with CRP ≤6 mg/ml (P = 0.0059). Tocilizumab reduced the risk for ≥10% decline in ppFVC in patients who were male, had earlier disease (<2 years duration), had IL-6 levels <10 pg/ml, or had anti-topoisomerase antibodies (ATA). In the SMART cohort, prognostic factors for ppFVC <70% were male sex, ATA, and low baseline FVC. Males had 3.3% lower FVC 1 year after disease onset (P < 0.001) and 0.6% faster yearly decline (P = 0.03) than females. CONCLUSION: Prognostic markers in SSc-ILD were similar between focuSSced and SMART. Male sex and inflammatory markers were associated with lower FVC but IL-6 ≥10 pg/ml was not predictive of response to tocilizumab. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02453256.
引用
- Ghuman A, Khanna D, Lin CJF, et al. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2024. PMID: 37228011. doi:10.1093/rheumatology/kead234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。